Recursion Pharmaceuticals

Contributing Author

Recent Articles by Recursion Pharmaceuticals

4 hours	Recursion Announces Vicki Goodman, M.D., as Incoming Chief Medical Officer RXRX GlobeNewswire
Feb-25	Recursion Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update RXRX +6.80% GlobeNewswire
Feb-23	Recursion To Be Featured in HighRes' Lightning Talk at NVIDIA GTC RXRX GlobeNewswire
Feb-23	Recursion to Participate in Upcoming Investor Conferences RXRX GlobeNewswire
Feb-18	Recursion to Report Fourth Quarter and Full Year 2025 Business Updates and Financial Results on February 25 RXRX GlobeNewswire
Feb-12	Recursion Reports Grant of Inducement Awards as Permitted by the Nasdaq Listing Rules RXRX GlobeNewswire
Jan-06	Recursion to Present at 44th Annual J.P. Morgan Healthcare Conference RXRX GlobeNewswire
Dec-01	Recursion Announces Webinar For Upcoming Clinical Data Readout on the TUPELO Phase 1b/2 Trial of REC-4881 in Familial Adenomatous Polyposis on December 8, 2025 RXRX -5.83% GlobeNewswire
Nov-05	Recursion Reports Third Quarter 2025 Financial Results and Provides Business Update RXRX GlobeNewswire
Nov-05	Recursion Announces CEO Transition Plan to Drive Next Phase of Growth RXRX GlobeNewswire
Nov-04	Recursion to Participate in Upcoming Investor Conferences RXRX -8.09% GlobeNewswire
Oct-28	Recursion to Report Third Quarter 2025 Business Updates and Financial Results on November 5th RXRX -6.19% GlobeNewswire
Aug-27	Recursion to Participate in Upcoming Investor Conferences RXRX GlobeNewswire
Aug-05	Recursion Reports Second Quarter 2025 Financial Results and Provides Business Update RXRX GlobeNewswire
Jul-29	Recursion to Report Second Quarter 2025 Business Updates and Financial Results on August 5th RXRX -5.71% GlobeNewswire
Jul-08	Recursion Acquires Full Rights to REV102, a Potential First-in-Class Oral ENPP1 Inhibitor for Hypophosphatasia RXRX +8.72% GlobeNewswire
Jun-06	MIT and Recursion Release Boltz-2: Next Generation AI Model to Predict Binding Affinity at Unprecedented Speed, Scale, and Accuracy RXRX +20.13% GlobeNewswire
May-30	Recursion to Participate in Upcoming Investor Conferences RXRX -6.07% GlobeNewswire
May-06	Recursion to Participate in Upcoming Investor Conferences RXRX -12.62% GlobeNewswire
May-05	Recursion Reports First Quarter 2025 Financial Results and Provides Business Update RXRX -16.58% GlobeNewswire

Recursion Pharmaceuticals

Recent Articles by Recursion Pharmaceuticals

Upgrade your FINVIZ experience